Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Healthcare Industry News ResMed (ASX: RMD) drops 8% as Astral recall clouds FY27 outlook ResMed fell 8% as FY27 sales guidance missed expectations. Astral recall costs and slower growth now test the ASX: RMD valuation. bySrinathAugust 9, 2026